# Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

> **NCT03643965** · PHASE3 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 365 (actual)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** Nefecon
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03643965
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2023-07-10
- **Final completion:** 2023-07-10
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643965, "Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03643965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*